Notably, LARP4B knockdown disrupts the metastasis-promoting role of a low dose of sorafenib and sensitizes HCC cells to a medium dose of sorafenib by inhibiting the activation of the EGFR pathway. The gene discussed is EGFR; the disease is hepatocellular carcinoma.